

Име и презиме	<b>Михајло Б. Јаковљевић</b>		
Звање	Редовни професор		
Назив институције у којој наставник ради са пуним радним временом и од када	Факултет медицинских наука, Универзитет у Крагујевцу	2006.	
Ужа научна односно уметничка област	Фармакологија и токсикологија		
Академска каријера			
	Година	Институција	Област
Избор у звање	2018.	Факултет медицинских наука, Универзитет у Крагујевцу	Фармакологија и токсикологија
Докторат	2008.	Факултет медицинских наука, Универзитет у Крагујевцу	Фармакологија и токсикологија
Специјализација	2013.	Факултет медицинских наука, Универзитет у Крагујевцу	Клиничка Фармакологија
Диплома	2003.	Факултет медицинских наука, Универзитет у Крагујевцу	Доктор медицине
Репрезентативне референце			
1.	<b>Jakovljevic M</b> , Potapchik E, Popovich L, Barik D, Getzen TE. Evolving Health Expenditure Landscape of the BRICS Nations and Projections to 2025. <i>Health Econ.</i> 2017;26(7):844-852.		
2.	<b>Jakovljevic MM</b> , Ogura S. Health Economics at the Crossroads of Centuries - From the Past to the Future. <i>Front Public Health.</i> 2016;4:115. doi: 10.3389/fpubh.2016.00115.		
3.	<b>Jakovljevic M</b> , Getzen TE. Growth of Global Health Spending Share in Low and Middle Income Countries. <i>Front Pharmacol.</i> 2016;7:21.		
4.	<b>Jakovljevic MM</b> , Netz Y, Buttigieg SC, Adany R, Laaser U, Varjagic M. Population aging and migration - history and UN forecasts in the EU-28 and its east and south near neighborhood - one century perspective 1950-2050. <i>Global Health.</i> 2018;14(1):30.		
5.	Jakovljevic M, Verhaeghe N, Souliotis K. Editorial: Challenges of Pharmacoeconomics in Global Health Arena. <i>Front Public Health.</i> 2018;6:368.		
6.	Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, <b>Jakovljevic M</b> , Khader Y, Linn S, Lad D, Mantovani L, Nong VM, Mokdad A, Naghavi M, Postma M, Roshandel G, Shackelford K, Sisay M, Nguyen CT, Tran TT, Xuan BT, Ukwaja KN, Vollset SE, Weiderpass E, Libby EN, Fitzmaurice C. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. <i>JAMA Oncol.</i> 2018;4(9):1221-1227.		
7.	Ogura S, Jakovljevic MM. Editorial: Global Population Aging - Health Care, Social and Economic Consequences. <i>Front Public Health.</i> 2018;6:335.		
8.	Dieleman J, Campbell M, ..., Jürisson M, <b>Jakovljevic MB</b> , ..., Murray CJL (Global Burden of Disease Health Financing Collaborator Network). Evolution and patterns of global health financing 1995-2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. <i>Lancet.</i> 2017;389(10083):1981-2004.		
9.	Jakovljevic M, Al Ahdab S, Jurisevic M, Mouselli S. Antibiotic Resistance in Syria: A Local Problem Turns Into a Global Threat. <i>Front Public Health.</i> 2018;6:212.		
10.	Dieleman JL, Campbell M, ..., Jürisson M, <b>Jakovljevic MB</b> , Javanbakht M, ..., Murray CJL (Global Burden of Disease Health Financing Collaborator Network). Future and potential spending on health 2015-40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. <i>Lancet.</i> 2017;389(10083):2005-2030.		
11.	<b>Jakovljevic M</b> , Camilleri C, Rancic N, Grima S, Jurisevic M, Grech K, Buttigieg SC. Cold War Legacy in Public and Private Health Spending in Europe. <i>Front Public Health.</i> 2018;6:215.		
12.	Iskrov GG, <b>Jakovljevic MM</b> , Stefanov RS. Budgetary Impact of Medicinal Therapies for Rare Diseases in Bulgaria. <i>Folia Med (Plovdiv).</i> 2018;60(1):79-91.		
13.	Jakovljevic M, Varavikova EA, Walter H, Wascher A, Pejic AV, Lesch OM. Alcohol Beverage Household Expenditure, Taxation and Government Revenues in Broader European WHO Region. <i>Front Pharmacol.</i> 2017;8:303.		
14.	Lim SS, Allen K, ..., Jahanmehr N, <b>Jakovljevic MB</b> , James P, ..., Murray CJ (GBD 2015 SDG Collaborators). Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet.</i> 2016;388(10053):1813-1850.		
15.	Ranabhat CL, Atkinson J, Park MB, Kim CB, <b>Jakovljevic M</b> . The Influence of Universal Health Coverage on Life Expectancy at Birth (LEAB) and Healthy Life Expectancy (HALE): A Multi-Country Cross-Sectional Study. <i>Front Pharmacol.</i> 2018;9:960.		
16.	Wang H, Naghavi M, ..., Jahanmehr N, <b>Jakovljevic MB</b> , James P, ..., Murray CJ (GBD 2015 Mortality and Causes of Death Collaborators). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet.</i> 2016;388(10053):1459-1544.		
17.	Boruzs K, Juhász A, Nagy C, Szabó Z, <b>Jakovljevic M</b> , Bíró K, Adány R. High Inequalities Associated With Socioeconomic Deprivation in Cardiovascular Disease Burden and Antihypertensive Medication in Hungary. <i>Front Pharmacol.</i> 2018;9:839.		
18.	Grima S, Spiteri JV, <b>Jakovljevic M</b> , Camilleri C, Buttigieg SC. High Out-of-Pocket Health Spending in Countries With a Mediterranean Connection. <i>Front Public Health.</i> 2018;6:145.		
19.	Sunjka ML, Pejic A, <b>Jakovljevic M</b> . Utilization patterns of complementary and alternative medicine in Australia, Canada and the United States: popularity of dietary supplements, mind-body and manipulative therapies. <i>Farmeconomia. Health economics and therapeutic pathways.</i> 2017;18(1):15-20.		
20.	Sándor J, Kósa K, Papp M, Fürjes G, Kőrösi L, <b>Jakovljevic M</b> , Adány R. Capitation-Based Financing Hampers the Provision of Preventive Services in Primary Health Care. <i>Front Public Health.</i> 2016;4:200.		
21.	<b>Jakovljevic M</b> , Lazarevic M, Milovanovic O, Kanjevac T. The New and Old Europe: East-West Split in Pharmaceutical Spending. <i>Front Pharmacol.</i> 2016;7:18.		
22.	Rancic N, <b>Jakovljevic M</b> . Long Term Health Spending Alongside Population Aging in N-11 Emerging Nations. <i>Eastern European Business and Economics Journal.</i> 2016;2(1):2-26.		
23.	Jakovljevic MB, Souliotis K. Pharmaceutical expenditure changes in Serbia and Greece during the global economic recession. <i>SEEPH</i> 2016; doi: 10.4119/UNIBI/SEEPH-2016-101.		
24.	<b>Jakovljevic M</b> , Kanjevac TV, Lazarevic M, Vladimir RB. Long Term Dental Work Force Build-Up and DMFT-12 Improvement in the European Region. <i>Front Physiol.</i> 2016;7:48.		
25.	<b>Jakovljevic M</b> , Groot W, Souliotis K. Editorial: Health Care Financing and Affordability in the Emerging Global Markets. <i>Front Public Health.</i> 2016;4:2.		
26.	<b>Jakovljevic MB</b> , Vukovic M, Fontanesi J. Life expectancy and health expenditure evolution in Eastern Europe-DiD and DEA analysis. <i>Expert Rev Pharmacoecon Outcomes Res.</i> 2016;16(4):537-46.		
27.	<b>Jakovljevic MM</b> . Comparison of historical medical spending patterns among the BRICS and G7. <i>J Med Econ.</i> 2016;19(1):70-6.		
28.	<b>Jakovljevic M</b> , Vukovic M, Chen CC, Antunovic M, Dragojevic-Simic V, Velickovic-Radovanovic R, Djendji MS, Jankovic N, Rankovic A, Kovacevic A, Antunovic M, Milovanovic O, Markovic V, Dasari BN, Yamada T. Do Health Reforms Impact Cost Consciousness of Health Care Professionals? Results from a Nation-Wide Survey in the Balkans. <i>Balkan Med J.</i> 2016;33(1):8-17.		
29.	<b>Jakovljevic MB</b> . BRIC's Growing Share of Global Health Spending and Their Diverging Pathways. <i>Front Public Health.</i> 2015;3:135.		

30.	<b>Jakovljevic M</b> , Laaser U. Population aging from 1950 to 2010 in seventeen transitional countries in the wider region of South Eastern Europe. SEEJPH. 2015; doi: 10.12908/SEEJPH-2014-42.
31.	<b>Jakovljevic M</b> , Jovanovic M, Rancic N, Vyssoki B, Djordjevic N. LAT software induced savings on medical costs of alcohol addicts' care--results from a matched-pairs case-control study. PLoS One. 2014;9(11):e111931.
32.	<b>Jakovljevic MB</b> , Getzen TE, Torbica A, Anegawa T. 10th World IHEA and ECHE Joint Congress: health economics in the age of longevity. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):781-3.
33.	Dagovic A, Matter Walstra K, Gutzwiller SF, Djordjevic N, Rankovic A, Djordjevic G, Kocic S, Vasiljevic D, Canovic P, Kovacevic A, Aleksandar D, Dragojevic Simic V, <b>Jakovljevic M</b> , Schwenkglens M. Resource use and costs of newly diagnosed cancer initial medical care. Eur J Oncol 2014;19(3):166-84.
34.	<b>Jakovljevic M</b> . The key role of leading emerging BRIC markets for the future of global health care. Ser J Exp Clin Res. 2014;15(3):139-143.
35.	<b>Jakovljevic MB</b> , Nakazono S, Ogura S. Contemporary generic market in Japan - key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):181-94.
36.	Ogura S, <b>Jakovljevic M</b> . Health financing constrained by population aging - an opportunity to learn from Japanese experience. Ser J Exp Clin Res. 2014;15(4):175-181.
40.	<b>Jakovljevic M</b> , Gutzwiller F, Schwenkglens M, Milovanovic O, Rancic N, Varjadic M, Stojadinovic D, Dagovic A, Matter-Walstra K. Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. J BUON. 2014;19(4):1111-20.
41.	<b>Jakovljevic MB</b> . Resource allocation strategies in Southeastern European health policy. Eur J Health Econ. 2013;14(2):153-9.
42.	<b>Jakovljevic M</b> , Riegler A, Jovanovic M, Djordjevic N, Patek K, Lesch O, Walter H. Serbian and Austrian alcohol-dependent patients: a comparison of two samples regarding therapeutically relevant clinical features. Alcohol Alcohol. 2013;48(4):505-8.
43.	<b>Jakovljevic M</b> , Mijailovic Z, Jovicic BP, Canovic P, Gajovic O, Jovanovic M, Petrovic D, Milovanovic O, Djordjevic N. Assessment of viral genotype impact to the cost-effectiveness and overall costs of care for PEG-interferon-2a + ribavirine treated chronic hepatitis C patients. Hepat Mon. 2013;13(6):e6750.
44.	<b>Jakovljevic MB</b> , Djordjevic V, Markovic V, Milovanovic O, Rancic NK, Cupara SM. Cross-sectional survey on complementary and alternative medicine awareness among health care professionals and students using CHBQ questionnaire in a Balkan country. Chin J Integr Med. 2013;19(9):650-5.
45.	<b>Jakovljevic M</b> , Varjadic M, Jankovic SM. Cost-effectiveness of ritodrine and fenoterol for treatment of preterm labor in a low-middle-income country: a case study. Value Health. 2008 Mar-Apr;11(2):149-53.
46.	Jovanovic M, <b>Jakovljevic M</b> . Inpatient detoxification procedure and facilities: financing considerations from an Eastern European perspective. Alcohol Alcohol. 2011;46(3):364-5.
47.	Vovk T, <b>Jakovljevic MB</b> , Kos MK, Jankovic SM, Mrhar A, Grabnar I. A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. Biol Pharm Bull. 2010;33(7):1176-82.
48.	<b>Jakovljevic MB</b> , Jankovic SM, Jankovic SV, Todorovic N. Inverse correlation of valproic acid serum concentrations and quality of life in adolescents with epilepsy. Epilepsy Res. 2008;80(2-3):180-3.
49.	<b>Jakovljevic M</b> , Yamada T. Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies. Front Pharmacol. 2017;8:662. doi: 10.3389/fphar.2017.00662.
50.	Ranabhat CL, Atkinson J, Park MB, Kim CB, <b>Jakovljevic M</b> . The Influence of Universal Health Coverage on Life Expectancy at Birth (LEAB) and Healthy Life Expectancy (HALE): A Multi-Country Cross-Sectional Study. Front Pharmacol. 2018;9:960. doi: 10.3389/fphar.2018.00960.
51.	Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, ..., <b>Jakovljevic MB</b> , ..., Naghavi M. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;4(11):1553-1568. doi: 10.1001/jamaoncol.2018.2706.
52.	Global Burden of Disease 2016 Injury Collaborators, Naghavi M, Marczak LB, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global Mortality From Firearms, 1990-2016. JAMA. 2018;320(8):792-814. doi: 10.1001/jama.2018.10060.
53.	GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. James SL, Theadom A, ... <b>Jakovljevic M</b> , ... Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):56-87. doi: 10.1016/S1474-4422(18)30415-0.
54.	GBD 2017 SDG Collaborators. Lozano R, Fullman N, ... <b>Jakovljevic M</b> , ..., Murray CJL. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):2091-2138. doi: 10.1016/S0140-6736(18)32281-5.
55.	GBD 2017 Population and Fertility Collaborators. Murray CJL, Callender CSKH, ..., <b>Jakovljevic M</b> , ..., Lim SS. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1995-2051. doi: 10.1016/S0140-6736(18)32278-5.
56.	GBD 2015 Eastern Mediterranean Region Diabetes and Chronic Kidney Disease Collaborators. Moradi-Lakeh M, El Bcheraoui C, ..., <b>Jakovljevic M</b> , ..., Mokdad AH. Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. Int J Public Health. 2018;63(Suppl 1):177-186. doi: 10.1007/s00038-017-1014-1.
57.	GBD 2017 Risk Factor Collaborators. Stanaway JD, Afshin A, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1923-1994. doi: 10.1016/S0140-6736(18)32225-6.
58.	Global Burden of Disease 2016 Greece Collaborators. Tyrovolas S, Kassebaum NJ, ..., <b>Jakovljevic M</b> , ..., Kotsakis GA. The burden of disease in Greece, health loss, risk factors, and health financing, 2000-16: an analysis of the Global Burden of Disease Study 2016. Lancet Public Health. 2018;3(8):e395-e406. doi: 10.1016/S2468-2667(18)30130-0.
59.	GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. James SL, Abate D, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7.
60.	GBD 2016 Healthcare Access and Quality Collaborators. Fullman N, Yearwood J, ..., <b>Jakovljevic M</b> , ..., Lozano R. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018;391(10136):2236-2271. doi: 10.1016/S0140-6736(18)30994-2.
61.	GBD 2017 Causes of Death Collaborators. Roth GA, Abate D, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7.
62.	GBD 2017 Mortality Collaborators. Dicker D, Nguyen G, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1684-1735. doi: 10.1016/S0140-6736(18)31891-9.
63.	Pejcic AV, Iskrov G, <b>Jakovljevic MM</b> , Stefanov R. Access to orphan drugs - comparison across Balkan countries. Health Policy. 2018;122(6):583-589.
64.	GBD 2017 DALYs and HALE Collaborators. Kyu HH, Abate D, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1859-1922.
65.	GBD 2015 Chronic Respiratory Disease Collaborators. Soriano JB, Abajobir AA, ..., <b>Jakovljevic M</b> , ..., Murray CJL, Vos T. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706.
66.	GBD 2016 Lower Respiratory Infections Collaborators. Troeger C, Blacker B, ..., <b>Jakovljevic M</b> , ..., Reiner RC Jr. Estimates of the global, regional, and

	national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Infect Dis.</i> 2018;18(11):1191-1210.
67.	GBD 2015 Healthcare Access and Quality Collaborators. Barber RM, Fullman N, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Electronic address: cjm@uw.edu; GBD 2015 Healthcare Access and Quality Collaborators. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet.</i> 2017;390(10091):231-266.
68.	Pejcic AV, Iskrov G, Raycheva R, Stefanov R, <b>Jakovljevic MM</b> . Transposition and implementation of EU rare disease policy in Eastern Europe. <i>Expert Rev Pharmacoecon Outcomes Res.</i> 2017;17(6):557-566.
69.	GBD 2016 SDG Collaborators. Fullman N, Barber RM, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet.</i> 2017 Sep 16;390(10100):1423-1459. doi: 10.1016/S0140-6736(17)32336-X. Epub 2017. Erratum in: <i>Lancet.</i> 2017 Oct 28;390(10106):e38.
70.	GBD 2016 Alcohol Collaborators. Griswold MG, Fullman N, ..., <b>Jakovljevic M</b> , ..., Murray CJL, Gakidou E. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet.</i> 2018;392(10152):1015-1035.
71.	GBD 2016 Mortality Collaborators. Wang H, Abajobir AA, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet.</i> 2017;390(10100):1084-1150.
72.	GBD 2016 Causes of Death Collaborators. Naghavi M, Abajobir AA, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet.</i> 2017;390(10100):1151-1210.
73.	GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Vos T, Abajobir AA, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet.</i> 2017;390(10100):1211-1259.
74.	GBD 2016 DALYs and HALE Collaborators. Hay SI, Abajobir AA, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet.</i> 2017;390(10100):1260-1344.
75.	GBD 2016 Risk Factors Collaborators. Gakidou E, Afshin A, ... <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet.</i> 2017;390(10100):1345-1422.
76.	GBD 2015 Neurological Disorders Collaborator Group. Feigin VL, Abajobir AA, ... <b>Jakovljevic M</b> , ..., Murray CJL, Vos T. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Neurol.</i> 2017;16(11):877-897.
77.	Global Burden of Disease Child and Adolescent Health Collaboration. Kassebaum N, Kyu HH, Zocckler L, Olsen HE, Thomas K, Pinho C, ... <b>Jakovljevic M</b> , ... Hay SI. Child and Adolescent Health From 1990 to 2015: Findings From the Global Burden of Diseases, Injuries, and Risk Factors 2015 Study. <i>JAMA Pediatr.</i> 2017;171(6):573-592.
78.	GBD 2015 Eastern Mediterranean Region Maternal Mortality Collaborators. Mokdad AH, Khalil I, ... <b>Jakovljevic M</b> , ..., Mokdad AH. Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>Int J Public Health.</i> 2017. doi: 10.1007/s00038-017-1004-3.
79.	GBD 2015 Eastern Mediterranean Region Cancer Collaborators. Fitzmaurice C, Alsharif U, ... <b>Jakovljevic M</b> , ..., Fitzmaurice C. Burden of cancer in the Eastern Mediterranean Region, 2005-2015: findings from the Global Burden of Disease 2015 Study. <i>Int J Public Health.</i> 2017. doi: 10.1007/s00038-017-0999-9.
80.	<b>Jakovljevic MM</b> , Arsenijevic J, Pavlova M, Verhaeghe N, Laaser U, Groot W. Within the triangle of healthcare legacies: comparing the performance of South-Eastern European health systems. <i>J Med Econ.</i> 2017;20(5):483-492.
81.	Pejcic AV, <b>Jakovljevic M</b> . Pharmaceutical expenditure dynamics in the Balkan countries. <i>J Med Econ.</i> 2017;20(10):1013-1017.
82.	GBD 2015 Eastern Mediterranean Region Mental Health Collaborators. Mokdad AH, Charara R. ... <b>Jakovljevic M</b> , ... Mokdad AH. The burden of mental disorders in the Eastern Mediterranean region, 1990-2015: findings from the global burden of disease 2015 study. <i>Int J Public Health.</i> 2017. doi: 10.1007/s00038-017-1006-1.
83.	<b>Jakovljevic M</b> . Population Ageing alongside Health Care Spending Growth. <i>Srp Ark Celok Lek</i> 2017; doi: 10.2298/SARH160906113J.
84.	<b>Jakovljevic M</b> , Varjadic M. Commentary: Do health care workforce, population, and service provision significantly contribute to the total health expenditure? An econometric analysis of Serbia. <i>Front Pharmacol.</i> 2017;8:33.
85.	Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Allen C, ..., <b>Jakovljevic M</b> , ..., Murray CJL, Naghavi M. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. <i>JAMA Oncol.</i> 2017;3(4):524-548.
86.	Mihailovic NM, Kocic SS, Trajkovic G, <b>Jakovljevic M</b> . Satisfaction with Health Services among the Citizens of Serbia. <i>Front Pharmacol.</i> 2017;8:50.
87.	GBD 2015 SDG Collaborators. Lim SS, Allen K, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet.</i> 2016;388(10053):1813-1850.
88.	GBD 2015 Mortality and Causes of Death Collaborators. Wang H, Naghavi M, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet.</i> 2016;388(10053):1459-1544.
89.	GBD 2015 Maternal Mortality Collaborators. Kassebaum NJ, Barber RM, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet.</i> 2016;388(10053):1775-1812. doi: 10.1016/S0140-6736(16)31470-2. Erratum in: <i>Lancet.</i> 2017;389(10064):e1.
90.	GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Vos T, Allen C, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet.</i> 2016;388(10053):1545-1602.
91.	GBD 2015 Risk Factors Collaborators. Forouzanfar MH, Afshin A, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet.</i> 2016;388(10053):1659-1724. doi: 10.1016/S0140-6736(16)31679-8. Erratum in: <i>Lancet.</i> 2017;389(10064):e1.
92.	GBD 2015 HIV Collaborators. Wang H, Wolock TM, ..., <b>Jakovljevic M</b> , ..., Murray CJL. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. <i>Lancet HIV.</i> 2016 Aug;3(8):e361-e387. doi: 10.1016/S2352-3018(16)30087-X. Erratum in: <i>Lancet HIV.</i> 2016;3(9):e408.
93.	<b>Jakovljevic M</b> . Commentary: Patient Cost Sharing and Medical Expenditures for the Elderly. <i>Front Pharmacol.</i> 2016;7:73.
94.	<b>Jakovljevic M</b> , Lazarevic M, Milovanovic O, Kanjevac T. The New and Old Europe: East-West Split in Pharmaceutical Spending. <i>Front Pharmacol.</i> 2016;7:18.
95.	Radevic S, Kocic S, <b>Jakovljevic M</b> . Self-Assessed Health and Socioeconomic Inequalities in Serbia: Data from 2013 National Health Survey. <i>Front Pharmacol.</i> 2016;7:140.
96.	Djordjevic N, Milovanovic DD, Radovanovic M, Radosavljevic I, Obradovic S, <b>Jakovljevic M</b> , Milovanovic D, Milovanovic JR, Jankovic S. CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy. <i>Eur J Clin Pharmacol.</i> 2016;72(4):439-45.
97.	Jovanovic M, <b>Jakovljevic M</b> . Regulatory Issues Surrounding Audit of Electronic Cigarette Charge Composition. <i>Front Psychiatry.</i> 2015;6:133.
98.	<b>Jakovljevic MM</b> , Lazarevic M, Jurisevic M, Jovanovic MR. When cure becomes an illness-abuse of addictive prescription medicines. <i>Front Pharmacol.</i> 2015;6:193.
99.	Kovacevic A, Dragojevic-Simic V, Tarabar D, Rancic N, Jacimovic N, Katic J, Dagovic A, <b>Jakovljevic M</b> . Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols. <i>Expert Rev Anticancer Ther.</i> 2015;15(8):963-70.

100.	Vuković M, Gvozdenović BS, Ranković M, McCormick BP, Vuković DD, Gvozdenović BD, Kastratović DA, Marković SZ, Ilić M, <b>Jakovljević MB</b> . Can didactic continuing education improve clinical decision making and reduce cost of quality? Evidence from a case study. <i>J Contin Educ Health Prof.</i> 2015;35(2):109-18.
101.	<b>Jakovljević MB</b> . A comment on the article: Stošić S, Karanović N. Health care economics in Serbia: current problems and changes. <i>Vojnosanit Pregl</i> 2014; 71(11):1055-61.
102.	Cupurdija V, Lazić Z, Petrović M, Mojsilović S, Cekerevac I, Rancić N, <b>Jakovljević M</b> . Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity. <i>J Bras Pneumol.</i> 2015;41(1):48-57.
103.	<b>Jakovljević MB</b> . Targeted immunotherapies overtaking emerging oncology market value based growth. <i>J BUON.</i> 2015;20(1):350-1.
104.	<b>Jakovljević MB</b> . Djordjević N, Jurisević M, Janković S. Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. <i>Expert Rev Pharmacoecon Outcomes Res.</i> 2015;15(3):521-30.
105.	<b>Jakovljević MB</b> , Jovanović M, Lesch OM. Accessibility and affordability of alcohol dependency medical care in Serbia. <i>Front Psychiatry.</i> 2015;5:192.
106.	Kovacević A, Dragojević-Simić V, Rancić N, Jurisević M, Gutzwiller FS, Matter-Walstra K, <b>Jakovljević M</b> . End-of-life costs of medical care for advanced stage cancer patients. <i>Vojnosanit Pregl.</i> 2015;72(4):334-41.
107.	Rancić N, Ranković A, Savić D, Abramović A, Rancić J, <b>Jakovljević M</b> . Intentional Self-Poisonings and Unintentional Poisonings of Adolescents With Nonfatal Outcomes. <i>Journal of Child and Adolescent Substance Abuse.</i> 2015;24(1):12-8.
108.	Rancić N, Erceg M, <b>Jakovljević M</b> , Savić S. Craniocerebral injuries in traffic accidents with fatal outcomes. <i>Australian Journal of Forensic Sciences.</i> 2014;46(2):180-93.
109.	<b>Jakovljević MB</b> , Djordjević V, Marković V, Milovanović O, Rancić NK, Cupara SM. Cross-sectional survey on complementary and alternative medicine awareness among health care professionals and students using CHBQ questionnaire in a Balkan country. <i>Chin J Integr Med.</i> 2013;19(9):650-5.
110.	Ranković A, Rancić N, Jovanović M, Ivanović M, Gajović O, Lazić Z, <b>Jakovljević M</b> . Impact of imaging diagnostics on the budget—are we spending too much? <i>Vojnosanit Pregl.</i> 2013;70(7):709-11.
111.	Ristić-Ignjatović D, Hinić D, <b>Jakovljević M</b> , Fountoulakis K, Siepera M, Rancić N. A ten-year study of depressive symptoms in Serbian medical students. <i>Acta Clin Croat.</i> 2013;52(2):157-63.
112.	Vuković M, Gvozdenović BS, Gajić T, Stamatović Gajić B, <b>Jakovljević M</b> , McCormick BP. Validation of a patient satisfaction questionnaire in primary health care. <i>Public Health.</i> 2012;126(8):710-8.
113.	Biorac N, <b>Jakovljević M</b> , Stefanović D, Perović S, Janković S. Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia. <i>Vojnosanit Pregl.</i> 2009;66(4):271-6.
114.	Vovk T, <b>Jakovljević MB</b> , Kos MK, Janković SM, Mrhar A, Grabnar I. A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. <i>Biol Pharm Bull.</i> 2010;33(7):1176-82.
115.	<b>Jakovljević M</b> , Jozef M, Vovk T, Janković S, Grabnar I. Current clinical evidence on topiramate pharmacokinetics. <i>Srp Arh Celok Lek.</i> 2009;137(7-8):444-8.
116.	Pejčić A, <b>Jakovljević M</b> . Economic impact of traditional medicine practice worldwide. <i>Traditional Medicine Research.</i> 2017;2(2): 60-74.
117.	Mihailović N, Radovanović S, Vasiljević D, Kocić S, <b>Jakovljević M</b> . Sociodemographic Characteristics Of The Over-The-Counter Drug Users In Serbia. <i>The Open Pharmacoeconomics and Health Economics Journal.</i> 2018;6(1):1-8. doi: 10.2174/1876824501806010001.
118.	Mihailović N, Radovanović S, Vasiljević D, Donović N, Radević S, <b>Jakovljević M</b> . The Influence of Sociodemographic Factors on the Use of Antihypertensive Drugs Among Adults in Serbia: Cross-Sectional Study. <i>Hospital Pharmacology.</i> 2017; 4(2):521-527.
119.	<b>Jakovljević MM</b> , Pejčić AV. Growth of Global Publishing Output of Health Economics in the Twenty-First Century: A Bibliographic Insight. <i>Front Public Health.</i> 2017;5:211. doi: 10.3389/fpubh.2017.00211.
120.	<b>Jakovljević M</b> , Malmose-Stapelfeldt C, Milovanović O, Rancić N, Bokonić D. Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries-Forecasts to 2020. <i>Front Public Health.</i> 2017;5:23. doi: 10.3389/fpubh.2017.00023.
121.	Sándor J, Kósa K, Papp M, Fűrjes G, Kőrösi L, <b>Jakovljević M</b> , Ádány R. Capitation-Based Financing Hampers the Provision of Preventive Services in Primary Health Care. <i>Front Public Health.</i> 2016;4:200.
122.	Milovanović DD, <b>Jakovljević M</b> , Scekić M, Djordjević N. Caffeine consumption patterns and determinants among adolescents in Serbia. <i>Int J Adolesc Med Health.</i> 2016;30(4). pii: /j/ijamh.2018.30.issue-4/ijamh-2016-0076/ijamh-2016-0076.
123.	<b>Jakovljević M</b> . Commentary: Implementing Pro-Poor Universal Health Coverage. <i>Front Public Health.</i> 2016;4:186.
124.	Mihailović N, Kocić S, <b>Jakovljević M</b> . Review of Diagnosis-Related Group-Based Financing of Hospital Care. <i>Health Serv Res Manag Epidemiol.</i> 2016;3:2333392816647892.
125.	<b>Jakovljević M</b> . The aging of Europe. The unexplored potential. <i>Farmeconomia. Health economics and therapeutic pathways</i> 2015;16(4):89-92.
126.	Vuković M, <b>Jakovljević M</b> . Structural validity and reliability of the healthcare professionals' economic reasoning questionnaire. <i>Hospital Pharmacology.</i> 2015;2(3):308-16.
127.	Petrusić T, <b>Jakovljević M</b> . Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska. <i>Front Public Health.</i> 2015;3:213.
128.	Rančić N, Šegrt Z, Ranković A, Kovačević A, Savić D, Abramović A, Dragojević-Simić V, <b>Jakovljević M</b> . Karakteristike uslovljene polom akutno otrovanih pacijenata. MD-Medical data. 2015;7(1):53-9.
129.	Velicković V, Simović A, Lazarević G, Lazarević M, <b>Jakovljević M</b> . Improvements in Neonatal and Childhood Medical Care - Perspective from the Balkans. <i>Front Public Health.</i> 2015;3:206.
130.	<b>Jakovljević MB</b> , Milovanović O. Growing Burden of Non-Communicable Diseases in the Emerging Health Markets: The Case of BRICS. <i>Front Public Health.</i> 2015;3:65.
131.	<b>Jakovljević M</b> , Tetsuji Y, Chia Ching C, Stevanović D, Jovanović M, Nikić Djuric K, Rancić N, Savić D, Biorac N, Mihajlović G, Janković S. Cost-Effectiveness of Depressive Episode Pharmacological Treatment. <i>Hospital Pharmacology.</i> 2015;2(1):235-45.
132.	<b>Jakovljević M</b> , Folic M, Dagović A. Hospital oncology costs among the cohort of elderly in an aging South-Eastern European nation. <i>Farmeconomia. Health economics and therapeutic pathways</i> 2015;16(1):3-5.
133.	Rančić J, Rančić N, Majstorović N, Biočanin V, Milosavljević M, <b>Jakovljević M</b> . Cost differentials of dental outpatient care across clinical dentistry branches. <i>Farmeconomia. Health economics and therapeutic pathways</i> 2015;16(1):25-32.
134.	<b>Jakovljević M</b> , Zugić A, Ranković A, Dagović A. Radiation therapy remains the key cost driver of oncology inpatient treatment. <i>J Med Econ.</i> 2015;18(1):29-36.
135.	<b>Jakovljević MB</b> . Health Expenditure Dynamics in Serbia 1995–2012. <i>Hospital Pharmacology.</i> 2014;1(3):180-3.
136.	<b>Jakovljević MB</b> . Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. <i>Farmeconomia. Health economics and therapeutic pathways</i> 2014;15(1):27-32.
137.	Vuković M, Gvozdenović B, <b>Jakovljević M</b> , Živanović P, Mitrović D, Plečić I, Ilić M, Is 28-Day Follow-Up Period Enough for Examining the Mortality after Resuscitation with Human Albumin? <i>Hospital Pharmacology.</i> 2014;1(1):1-8.
138.	<b>Jakovljević M</b> . Recent developments among world's leading generic markets. <i>Med J (Krag).</i> 2014;48(3):140-2.
139.	<b>Jakovljević M</b> , Lazić Z, Verhaeghe N, Janković S, Gajović O, Annemans L. Direct medical costs of COPD diagnosis and treatment, Eastern vs. Western European country - examples of Serbia and Belgium, SEEEd Medical Publishers. <i>Farmeconomia. Health economics and therapeutic pathways</i> 2013;14(4):161-8.
140.	<b>Jakovljević M</b> , Ranković A, Rancić N, Jovanović M, Ivanović M, Gajović O, Lazić Z. Radiology Services Costs and Utilization Patterns estimates in Southeastern Europe - A Retrospective Analysis from Serbia. <i>Value in Health Regional</i> 2013; 2(2):218–25.
141.	Dagović A, Zugić A, <b>Jakovljević M</b> . Macroeconomic policy impact on oncology-related public expenditure in an emerging European market – signs of early recovery. <i>Ser J Exp Clin Res.</i> 2014;16(1):43-50.

142.	Lazic Z, Gajovic O, Tanaskovic I, Milovanovic D, Atanasijevic D, <b>Jakovljevic M</b> . GOLD Stage Impact on COPD Direct Medical Costs in Elderly. Health Behav and Pub Health. 2012;2(3):1-7.
143.	<b>Jakovljevic M</b> , Milovanovic O, Pharmacological in vitro models in pre-clinical drug testing - example of hSERT transfected human embryonic kidney cells. Acta Medica Medianae. 2012;1(2):34-38.
144.	<b>Jakovljevic M</b> , Cupurdija V, Lazic Z, Cost of illness of community-acquired pneumonia. Review of the literature and possible strategies in the Serbian health care setting, SEEd Medical Publishers. Farneconomia. Health economics and therapeutic pathways 2013;14(4):133-9.
145.	Cupara C, Djordjevic B, <b>Jakovljevic M</b> . Current legal status and research on complementary and alternative medicine in Serbia. J Altern Med Res. 2013;5(3):195-8.
146.	Savic D, <b>Jakovljevic M</b> . Estimate of clinical outcomes from the patient perspective is important for clinical decision making. Rational treatment. 2012;4(1):47-9.
147.	Rankovic A, Milovanovic J, Jankovic SV, Todorovic N, Rancic N, Jestrovic N, Grabnar I, Jankovic SM, <b>Jakovljevic M</b> . Role of anticonvulsant therapeutic drug monitoring in improving clinical outcomes: an example of 12 adult epilepsy patients. Ser J Exp Clin Res. 2012;13(2):69-71.
148.	Rancic N, Mirjana J, Lazic D, Jakovljevic M. Blood alcohol levels impact to the fatal traffic accidents rates. Medicinski Casopis 2012; 46(3):160-7.
149.	Rančić N, Ranković A, Petronijević M, Jovanović J, <b>Jakovljević M</b> . Analysis of toxicity and tolerance of contrast agents in conventional CT and MR. Materia Medica. 2012;28(3):673-82.
150.	<b>Jakovljevic M</b> , Jovanovic M, Lazic Z, Jakovljevic V, Djukic A, Velickovic R, Antunovic M. Current efforts and proposals to reduce healthcare costs in Serbia. Ser J Exp Clin Res. 2011;12(4):161-3.
151.	<b>Jakovljevic M</b> . Pharmacoeconomic assessment based decision making in delivering health care being on the rise among Eastern European and Balkans policy makers. ISPOR Connections. 2011;17(6).
152.	<b>Jakovljevic M</b> , Jovanovic M, Nikic K, Radovanovic A, Pirkovic I, Djukic Dejanovic S and Yamada T. Acute Alcohol Detoxification Costs in Upper-Middle Income: Western Balkans. Health Behavior and Public Health. 2011;1(2):1-7.
153.	<b>Jakovljević M</b> , Jovanović M. Sadašnji status i troškovi lečenja opioidne zavisnosti u domaćem zdravstvenom sektoru. Psihijatrija danas. 2011;43(2):197-9.
154.	Radovanovic A, Dagovic A, <b>Jakovljevic M</b> . Economics of cancer related medical care: estimates worldwide and available domestic evidence. Arch Oncol. 2011;19(3-4):59-63.
155.	Kovačević A, Tarabar D, <b>Jakovljević M</b> , Dragojević Simić V. Colorectal carcinoma chemotherapy: current status and future directions. Pharmaca Serbica. 2011;3(3-4):20-5.
156.	Rančić N, Savić D, <b>Jakovljević M</b> . Analytical methods of toxin detection in human samples: Applicability in medical care of acutely poisoned patients. Scientific Journal of Emergency Medicine Halo 94. 2011;17(1):34-44.
157.	<b>Jakovljevic M</b> , Jankovic SV, Todorovic N, Milovanovic J, Jankovic S. Population pharmacokinetics of valproic acid in patients with epilepsy. Medicinski pregled. 2010. 63(5-6):349-55.
158.	<b>Jakovljevic M</b> , Stepanovic M, Available treatment approaches of H1N1 acute infection and its clinical complications. Acta medica Medianae.2010;49(3):76-82.
159.	<b>Jakovljevic M</b> , Markovic V, Folic M. Entamoeba histolytica infections, identification and treatment. Rational Treatment. 2010;2(1):25-30.
160.	Jestrovic N, Folic M, Markovic V, <b>Jakovljevic M</b> . Acute pulmonary edema in outpatient conditions – causes , evolution and treatment. ABC emergency medicine journal. 2009;9(3):159-64.

Збирни подаци научне, односно уметничке и стручне активности наставника

Укупан број цитата	Science Citation Index Web of Science	<b>3164</b> <a href="http://www.researcherid.com/ProfileView.action?returnCode=ROUTER.Unauthorized&amp;Init=Yes&amp;SrcApp=CR&amp;queryString=KG0UuZjN5WmP6yAsUHIBKitzRBFZE%252BmytNR50mz1BE%253D">http://www.researcherid.com/ProfileView.action?returnCode=ROUTER.Unauthorized&amp;Init=Yes&amp;SrcApp=CR&amp;queryString=KG0UuZjN5WmP6yAsUHIBKitzRBFZE%252BmytNR50mz1BE%253D</a>
	Scopus	<b>6327</b> <a href="https://www.scopus.com/authid/detail.uri?authorId=14318929700">https://www.scopus.com/authid/detail.uri?authorId=14318929700</a>
Укупан број радова са SCI или (SSCI) листе	<b>111</b>	
Тренутно учешће на пројектима	Домаћи	<b>2</b>
	Међународни	<b>6</b>
Усавршавања	Професор Михајло Јаковљевић, служи у својству Националног стручњака - представника Републике Србије у Саветодавном Одбору за Истраживање Здравља Светске Здравствене Организације (WHO EACHR) при Кабинету Директора СЗО за Европски Регион (53 земље). Шеф је Катедре за Глобално Здравље Економију и Политику на Докторским студијама у својој матичној установи. Добитник је годишње награде Српског Фармаколошког Друштва „Професор Владислав Варагић“ за најистакнутији научни допринос међу фармаколозима до 40 година старости у 2017. години.	